Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion type Assertion NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_head.
- NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion description "[A number of approaches have been investigated: (1) a humanized monoclonal antibody against HER2, rhuMAbHER2 (trastuzumab), which is already approved for clinical use in the treatment of patients with metastatic breast cancer; (2) tyrosine kinase inhibitors, such as emodin, which block HER2 phosphorylation and its intracellullar signaling; (3) active immunotherapy, such as vaccination; and (4) heat shock protein (Hsp) 90-associated signal inhibitors, such as radicicol derivatives, which induce degradation of tyrosine kinase receptors, such as HER2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_provenance.
- NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion evidence source_evidence_literature NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_provenance.
- NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion SIO_000772 11180765 NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_provenance.
- NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion wasDerivedFrom befree-2016 NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_provenance.
- NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_assertion wasGeneratedBy ECO_0000203 NP307498.RAWpU7QFUAYIRCmsNioWJG5kUPVg-MTuZ52mrGSVtxooI130_provenance.